<!DOCTYPE html>
<html lang="en" dir="ltr">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <link rel="manifest" href="/manifest.json">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">

  <title>Neuroendocrine Tumors (NET): Information & Treatment | StopMyCancer</title>
  <meta name="description" content="Understanding neuroendocrine tumors (NET). Carcinoid tumors, pancreatic NETs, symptoms, diagnosis, surgery, chemotherapy, somatostatin analogs, and targeted therapy.">
  <meta name="keywords" content="neuroendocrine tumor, NET, carcinoid, pancreatic neuroendocrine tumor, pNET, somatostatin, sunitinib, everolimus, chemotherapy">
  <meta name="author" content="StopMyCancer">
  <link rel="canonical" href="https://stopmycancer.com/cancers/neuroendocrine/">

  <meta property="og:type" content="article">
  <meta property="og:title" content="Neuroendocrine Tumors (NET): Information & Treatment">
  <meta property="og:description" content="Comprehensive guide to neuroendocrine tumors, carcinoid tumors, and treatment options.">
  <meta property="og:url" content="https://stopmycancer.com/cancers/neuroendocrine/">
  <meta property="og:site_name" content="StopMyCancer">
  <meta property="og:locale" content="en_US">

  <link rel="preconnect" href="https://fonts.googleapis.com">
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
  <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700;800&display=swap" rel="stylesheet">
  <link rel="stylesheet" href="/css/styles.css">
  <link rel="icon" type="image/svg+xml" href="data:image/svg+xml,<svg xmlns='http://www.w3.org/2000/svg' viewBox='0 0 100 100'><text y='.9em' font-size='90'>üõ°Ô∏è</text></svg>">
</head>
<body>

  <a href="#main" class="skip-link">Skip to main content</a>

  <header class="header" role="banner">
    <div class="header__inner">
      <a href="/" class="header__logo" aria-label="StopMyCancer Home">
        <div class="header__logo-icon" aria-hidden="true">S</div>
        Stop<span>My</span>Cancer
      </a>

      <nav class="header__nav" role="navigation" aria-label="Main navigation">
        <a href="/cancers/" class="header__nav-link">Cancer Types</a>
        <a href="/navigate/" class="header__nav-link">Navigate</a>
        <a href="/stories/" class="header__nav-link">Stories</a>
        <a href="/access/" class="header__nav-link">Access &amp; Equity</a>
        <a href="/tools/pathology-translator" class="header__nav-link">Translator Tool</a>
        <a href="/about/" class="header__nav-link">About</a>
      </nav>

      <div class="header__actions">
        <div class="lang-switcher">
          <button class="lang-switcher__btn" aria-haspopup="true" aria-expanded="false" aria-label="Change language">
            <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><circle cx="12" cy="12" r="10"></circle><line x1="2" y1="12" x2="22" y2="12"></line><path d="M12 2a15.3 15.3 0 0 1 4 10 15.3 15.3 0 0 1-4 10 15.3 15.3 0 0 1-4-10 15.3 15.3 0 0 1 4-10z"></path></svg>
            EN
            <svg width="12" height="12" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><path d="M6 9l6 6 6-6"></path></svg>
          </button>
          <div class="lang-switcher__dropdown" role="menu">
            <a href="/cancers/neuroendocrine/" class="lang-switcher__option lang-switcher__option--active" role="menuitem">English</a>
          </div>
        </div>

        <button class="mobile-toggle" aria-label="Open menu" aria-expanded="false" aria-controls="mobile-nav">
          <span class="mobile-toggle__line"></span>
          <span class="mobile-toggle__line"></span>
          <span class="mobile-toggle__line"></span>
        </button>
      </div>
    </div>
  </header>

  <nav class="mobile-nav" id="mobile-nav" role="navigation" aria-label="Mobile navigation">
    <a href="/cancers/" class="mobile-nav__link">Cancer Types</a>
    <a href="/navigate/" class="mobile-nav__link">Navigate</a>
    <a href="/stories/" class="mobile-nav__link">Stories</a>
    <a href="/access/" class="mobile-nav__link">Access &amp; Equity</a>
    <a href="/tools/pathology-translator" class="mobile-nav__link">Pathology Translator</a>
    <a href="/about/" class="mobile-nav__link">About</a>
  </nav>

  <main id="main">

    <section class="page-header">
      <div class="container">
        <div class="breadcrumbs" role="navigation" aria-label="Breadcrumbs">
          <a href="/">Home</a> <span aria-hidden="true">/</span> <a href="/cancers/">Cancer Types</a> <span aria-hidden="true">/</span> <span>Neuroendocrine Tumors</span>
        </div>
        <h1>Neuroendocrine Tumors (NET)</h1>
        <p class="page-header__subtitle">Understanding slow-growing neuroendocrine tumors. Carcinoid syndrome, diagnosis, surgery, and medical management.</p>
      </div>
    </section>

    <section class="main-content">
      <div class="container">
        <div class="grid grid--content-sidebar">

          <article class="article">

            <section class="summary">
              <p><strong>Neuroendocrine tumors (NETs) are a heterogeneous group of cancers arising from neuroendocrine cells.</strong> They are often slow-growing and may be discovered incidentally. Many NETs are indolent (slow-growing) but some are aggressive. Treatment depends on grade, stage, and location.</p>
            </section>

            <section>
              <h2>What Are Neuroendocrine Tumors?</h2>
              <p>NETs arise from neuroendocrine cells scattered throughout the body (lungs, GI tract, pancreas, adrenal glands). These cells secrete hormones and bioactive substances. When neoplastic, they can produce excessive hormones causing carcinoid syndrome or hormone-related symptoms.</p>
              <p><strong>Key fact:</strong> Many NETs are incidental findings on imaging for unrelated reasons. Grade (Ki-67 proliferation index) determines aggressiveness and treatment approach.</p>
            </section>

            <section>
              <h2>Types &amp; Sites</h2>
              <ul>
                <li><strong>GI NETs:</strong> Foregut (stomach, duodenum), midgut (small bowel, appendix), hindgut (colon, rectum). Different sites have different behavior.</li>
                <li><strong>Pancreatic NETs (pNETs):</strong> Insulinomas, gastrinomas, VIPomas. Can be functional (hormone-secreting) or non-functional.</li>
                <li><strong>Lung NETs:</strong> Typical carcinoid (low-grade) or atypical carcinoid (higher-grade).</li>
                <li><strong>Other sites:</strong> Thyroid, adrenal, pituitary.</li>
              </ul>
            </section>

            <section>
              <h2>Risk Factors</h2>
              <ul>
                <li><strong>Genetic syndromes:</strong> MEN-1, NF-1, VHL, SDHX mutations increase risk.</li>
                <li><strong>Age:</strong> Can occur at any age; typical presentation 50-70 years.</li>
                <li><strong>Chronic inflammation:</strong> Achlorhydria (no stomach acid), chronic atrophic gastritis.</li>
              </ul>
            </section>

            <section>
              <h2>Symptoms</h2>
              <ul>
                <li><strong>Carcinoid syndrome:</strong> Flushing, diarrhea, wheezing, heart problems (from serotonin secretion). Typically indicates metastatic disease.</li>
                <li><strong>Functional symptoms:</strong> Depends on hormone: hypoglycemia (insulinoma), severe diarrhea (gastrinoma), hypokalemia (VIPoma).</li>
                <li><strong>Mass effect:</strong> Obstruction, bleeding, abdominal pain.</li>
                <li><strong>Incidental:</strong> Many discovered on imaging for unrelated reasons.</li>
              </ul>
            </section>

            <section>
              <h2>Diagnosis</h2>
              <p><strong>Diagnostic approach:</strong></p>
              <ul>
                <li><strong>Biochemical markers:</strong> 24-hour urine 5-HIAA (serotonin metabolite), chromogranin A, gastrin, insulin levels depending on symptoms.</li>
                <li><strong>Imaging:</strong> CT, MRI, endoscopy (for GI NETs).</li>
                <li><strong>Functional imaging:</strong> Somatostatin receptor scintigraphy, PET imaging to detect neuroendocrine uptake.</li>
                <li><strong>Biopsy:</strong> Confirms diagnosis and allows immunohistochemistry (synaptophysin, chromogranin).</li>
                <li><strong>Grade:</strong> Ki-67 index and mitotic count determine low (G1), intermediate (G2), or high-grade (G3).</li>
              </ul>
            </section>

            <section>
              <h2>Staging &amp; Prognosis</h2>
              <p>Uses TNM system with grade. Grade is prognostic:</p>
              <ul>
                <li><strong>G1 (low-grade):</strong> Ki-67 &lt;2%. Often indolent; 5-year survival 80-90%+.</li>
                <li><strong>G2 (intermediate):</strong> Ki-67 3-20%. More aggressive; 5-year survival 40-80%.</li>
                <li><strong>G3 (high-grade):</strong> Ki-67 &gt;20%. Very aggressive; 5-year survival &lt;40%.</li>
              </ul>
            </section>

            <section>
              <h2>Treatment Options</h2>

              <h3>Surgery</h3>
              <p>Often first-line for localized disease. Curative if complete resection achievable. Even with metastases, debulking can improve quality of life.</p>

              <h3>Somatostatin Analogs</h3>
              <p>Octreotide, lanreotide. Reduce hormone secretion and slow tumor growth in some patients. Used for carcinoid syndrome symptom relief and as maintenance therapy.</p>

              <h3>Targeted Therapy</h3>
              <p><strong>mTOR inhibitors:</strong> Everolimus improves progression-free survival in pNETs. Tyrosine kinase inhibitors (sunitinib) also used for pNETs.</p>

              <h3>Chemotherapy</h3>
              <p>For high-grade NETs or advanced disease. Platinum-based chemotherapy used for high-grade NETs; less effective in low-grade tumors.</p>

              <h3>Peptide Receptor Radionuclide Therapy (PRRT)</h3>
              <p>Using radiolabeled somatostatin analogs (Lu-177 dotatate, Y-90 dotatate). Targets NET cells expressing somatostatin receptors. Emerging standard for advanced NETs.</p>

              <h3>Hepatic-Directed Therapy</h3>
              <p>For metastases to liver: embolization, chemoembolization, or radioembolization.</p>
            </section>

            <section>
              <h2>Carcinoid Syndrome Management</h2>
              <ul>
                <li>Somatostatin analogs (mainstay)</li>
                <li>Dietary management (avoid triggers: alcohol, spicy foods)</li>
                <li>Antihistamines and 5-HT3 antagonists for symptom relief</li>
                <li>Echocardiogram screening (carcinoid can affect heart valves)</li>
              </ul>
            </section>

            <section>
              <h2>Prognosis &amp; Follow-Up</h2>
              <p>Highly variable based on grade and site. Low-grade NETs often have excellent long-term survival even with metastases. Regular monitoring with biochemical markers and imaging guides treatment decisions.</p>
            </section>

            <section class="urgent-box">
              <h2>Seek Immediate Care If You Experience:</h2>
              <ul>
                <li>Severe flushing episodes with tachycardia or bronchospasm</li>
                <li>Severe diarrhea leading to dehydration</li>
                <li>Signs of carcinoid crisis (severe symptoms during anesthesia/stress)</li>
              </ul>
            </section>

            <section>
              <h2>Key Questions for Your Doctor</h2>
              <ul>
                <li>What grade and stage is my NET?</li>
                <li>Is my tumor functional? What hormone is it secreting?</li>
                <li>Is surgery an option?</li>
                <li>Do I need somatostatin analog therapy?</li>
                <li>Am I a candidate for PRRT or other targeted therapies?</li>
                <li>What surveillance plan should I follow?</li>
              </ul>
            </section>

          </article>

        </div>
      </div>
    </section>

  </main>

  <footer class="footer">
    <div class="container">
      <div class="footer__content">
        <div class="footer__section">
          <h3>StopMyCancer</h3>
          <p>Your cancer. Explained. Supported. Navigated.</p>
        </div>
        <div class="footer__section">
          <h4>Navigation</h4>
          <ul>
            <li><a href="/cancers/">Cancer Types</a></li>
            <li><a href="/navigate/">Navigate</a></li>
            <li><a href="/stories/">Stories</a></li>
            <li><a href="/access/">Access &amp; Equity</a></li>
          </ul>
        </div>
        <div class="footer__section">
          <h4>Resources</h4>
          <ul>
            <li><a href="/tools/pathology-translator">Pathology Translator</a></li>
            <li><a href="/about/">About</a></li>
            <li><a href="https://github.com/fantravel1/stopmycancer" target="_blank">GitHub</a></li>
          </ul>
        </div>
      </div>
      <div class="footer__bottom">
        <p>&copy; 2025 StopMyCancer. Licensed under CC BY 4.0.</p>
      </div>
    </div>
  </footer>

  <script src="/js/main.js"></script>

</body>
</html>
